Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases

Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B
Verena EngelstaedterDoris Mayr

Abstract

Her-2/neu gene amplification is an established prognostic factor in breast cancer, and Her-2/neu protein is the target of the therapeutic monoclonal antibody Herceptin. More recently, topoisomerase IIα became a new focus of breast cancer research because of its role as a target for anthracycline therapy. Therefore, we compared Her-2/neu and topoisomerase IIα amplification/deletion in a large series of advanced breast cancer using fluorescence in situ hybridization. Paraffin-embedded archival tissue from 245 patients was retrieved and assessed for Her-2/neu and topoisomerase IIα amplification/deletion by fluorescence in situ hybridization according to standard protocols. Relation to clinical data and survival was sought. A total of 245 cases were analyzed. Amplification for Her-2/neu was seen in 57 cases (23.3%), and for topoisomerase IIα in 12 cases (4.9%). Coamplification was found in 9 samples (3.7%), 3 cases (1.2%) showed amplification of topoisomerase IIα but not of Her-2/neu, and 48 samples (19.8%) displayed amplification for Her-2/neu but not for topoisomerase IIα. Correlation to the histologic type, the stage, or the grade could not be found. Only the amplification of topoisomerase IIα was associated with very poor outco...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A GustersonR Reed
Mar 5, 1999·Breast Cancer Research and Treatment·M D PegramD J Slamon
May 29, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·P L DepowskiJ S Ross
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G PaulettiD J Slamon
Jun 1, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GaspariniA Morabito
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Jan 30, 2007·Breast Cancer Research and Treatment·Edurne ArriolaJorge S Reis-Filho
Oct 9, 2007·Pathology Oncology Research : POR·Asli Rehber BeserNejat Dalay
May 10, 2008·Acta Oncologica·Kirsten Vang NielsenHenning T Mouridsen
Apr 30, 2009·Journal of the National Cancer Institute·F P O'MalleyK I Pritchard
Dec 1, 2009·Molecular Oncology·Kirsten Vang NielsenBent Ejlertsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.